Seqirus – Banksia
Project Banksia involves the design, construction, validation and registration of a new state-of-the-art biopharmaceutical facility, which will use innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs. This will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere. The facility will also manufacture CSL Seqirus’ proprietary adjuvant MF59R and will produce unique products important to Australia’s public health needs – including antivenom for Australian snakes, spiders and marine creatures, and the world’s only human vaccine for Q-Fever.
Pure Pipings scope of work is centred around FCC Level 1 Purification, Products of National Significance (PNS) building and Administration & Laboratories (ADL) building. Process and Utilities services installed include-
- Water for injection
- Pure Water
- Product
- Sodium Hydroxide 28% solution
- Citric Acid 50% solution
- Nitrogen Gas
- Argon Gas
- Carbon Dioxide Gas
- Compressed Air & Filtered Compressed Air
- Buffer
- CIP Supply / Return
- Drain to Effluent Decontamination
- Drain to Effluent Treatment
- Exhaust
Parkville HP Compressed Air Upgrade
This project involved expanding the capacity of the site compressed air system.
Installation of two new compressors, two wet receivers, two new air preparation trains external to the compressor house and refrigerated drier.
This incorporated back end work (in main headers etc) to accommodate the installation, all new pipes being sched 10 6-8”.
Modification to existing receivers pipework to maintain original receivers as back up to new system.
Seqirus – January – May 2019
Project Value – $350,000.
